Intracellular MMP-2 activity in skeletal muscle is associated with type II fibers

Journal of Cellular Physiology

Volumn 230, Issue 1, 2015, Pages 160-169

  Hadler Olsen, Elin ^a   Solli, Ann Iren ^a   Hafstad, Anne ^a   Winberg, Jan Olof ^a   Uhlin Hansen, Lars ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EDETIC ACID; ENZYME INHIBITOR; GELATINASE A; GELATINASE B; GELATINASE INHIBITOR; METALLOPROTEINASE INHIBITOR; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; CYCLOPEPTIDE; CYSTEINE PROTEINASE INHIBITOR; GELATINASE; GRENYHGCTTHWGFTLC PEPTIDE; LEUCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ENZYME ACTIVITY; FAST MUSCLE FIBER; GASTROCNEMIUS MUSCLE; IMMUNOGOLD ELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MOUSE; MUSCLE CELL; MUSCLE CONTRACTILITY; MYOBLAST; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RUNNING; SKELETAL MUSCLE; SLOW MUSCLE FIBER; TREADMILL EXERCISE; ZYMOGRAPHY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; ENZYMOLOGY; MALE; METABOLISM; SARCOMERE;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CYSTEINE PROTEINASE INHIBITORS; EDETIC ACID; GELATINASES; LEUCINE; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; MUSCLE CELLS; MUSCLE FIBERS, FAST-TWITCH; MUSCLE FIBERS, SLOW-TWITCH; MYOBLASTS; PEPTIDES, CYCLIC; PHYSICAL CONDITIONING, ANIMAL; SARCOMERES;

EID: 84910028968     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24694     Document Type: Article

References (49)

1. Alameddine HS. 2012. Matrix metalloproteinases in skeletal muscles: friends or foes. Neurobiol Dis 48:508-518.
2. Alfonso-Jaume MA, Bergman MR, Mahimkar R, Cheng S, Jin ZQ, Karliner JS, Lovett DH. 2006. Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol 291: H1838-H1846.
3. Ali MA, Chow AK, Kandasamy AD, Fan X, West LJ, Crawford BD, Simmen T, Schulz R. 2012. Mechanisms of cytosolic targeting of matrix metalloproteinase-2. J Cell Physiol 227:3397-3404.
4. Ali MA, Fan X, Schulz R. 2011. Cardiac sarcomeric proteins: novel intracellular targets of matrix metalloproteinase-2 in heart disease. Trends Cardiovasc Med 21:112-118.
5. Balon TW, Nadler JL. 1994. Nitric oxide release is present from incubated skeletal muscle preparations. J Appl Physiol 77:2519-2521.
6. Bolli R, Marban E. 1999. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 79:609-634.
7. Brinckerhoff CE, Matrisian LM. 2002. Matrix metalloproteinases: A tail of a frog that became a prince. Nat Rev Mol Cell Biol 3:207-214.
8. Carmeli E, Beiker R, Maor M, Kodesh E. 2010. Increased iNOS, MMP-2, and HSP-72 in skeletal muscle following high-intensity exercise training. J Basic Clin Physiol Pharmacol 21:127-146.
9. Carmeli E, Moas M, Lennon S, Powers SK. 2005. High intensity exercise increases expression of matrix metalloproteinases in fast skeletal muscle fibres. Exp Physiol 90:613-619.
10. Cauwe B, Opdenakker G. 2010. Intracellular substrate cleavage: A novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 45:351-423.
11. Chen X, Li Y. 2009. Role of matrix metalloproteinases in skeletal muscle: Migration, differentiation, regeneration and fibrosis. Cell Adh Migr 3:337-341.
12. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. 2000. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101:1833-1839.
13. Coussens LM, Fingleton B, Matrisian LM. 2002. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295:2387-2392.
14. Dahiya S, Bhatnagar S, Hindi SM, Jiang C, Paul PK, Kuang S, Kumar A. 2011. Elevated levels of active matrix metalloproteinase-9 cause hypertrophy in skeletal muscle of normal and dystrophin-deficient mdx mice. Hum Mol Genet 20:4345-4359.
15. Deus AP, Bassi D, Simoes RP, Oliveira CR, Baldissera V, Marqueti RDE, Araujo C, Arena HS, Borghi-Silva R. 2012. MMP(-2) expression in skeletal muscle after strength training. Int J Sports Med 33:137-141.
16. Engel AG, Tice LW. 1966. Cytochemistry of phosphatases of the sarcoplasmic reticulum. I. Biochemical studies. J Cell Biol 31:473-487.
17. Fedarko NS, Jain A, Karadag A, Fisher LW. 2004. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J 18:734-736.
18. Freise C, Erben U, Muche M, Farndale R, Zeitz M, Somasundaram R, Ruehl M. 2009. The alpha 2 chain of collagen type VI sequesters latent proforms of matrix-metalloproteinases and modulates their activation and activity. Matrix Biol 28:480-489.
19. Fukushima K, Nakamura A, Ueda H, Yuasa K, Yoshida K, Takeda S, Ikeda S. 2007. Activation and localization of matrix metalloproteinase-2 and-9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ). BMC Musculoskelet Disord 8:54.
20. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. 2011a. Regulation of matrix metalloproteinase activity in health and disease 1. FEBS J 278:28-45.
21. Hadler-Olsen E, Kanapathippillai P, Berg E, Svineng G, Winberg JO, Uhlin-Hansen L. 2010. Gelatin in situ zymography on fixed, paraffin-embedded tissue: Zinc and ethanol fixation preserve enzyme activity. J Histochem Cytochem 58:29-39.
22. Hadler-Olsen E, Winberg JO, Reinholt FP, Larsen T, Uhlin-Hansen L, Jenssen T, Berg E, Kolset SO. 2011b. Proteases in plasma and kidney of db/db mice as markers of diabetesinduced nephropathy. ISRN Endocrinol 2011:832642.
23. Hafstad AD, Boardman NT, Lund J, Hagve M, Khalid AM, Wisloff U, Larsen TS, Aasum E. 2011. High intensity interval training alters substrate utilization and reduces oxygen consumption in the heart. J Appl Physiol 111:1235-1241.
24. Heikkila P, Suojanen J, Pirila E, Vaananen A, Koivunen E, Sorsa T, Salo T. 2006. Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. Int J Cancer 118:2202-2209.
25. Hill JW, Poddar R, Thompson JF, Rosenberg GA, Yang Y. 2012. Intranuclear matrix metalloproteinases promote DNA damage and apoptosis induced by oxygen-glucose deprivation in neurons. Neuroscience 220:277-290.
26. Kumar A, Bhatnagar S. 2010. Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice. Am J Pathol 177:248-260.
27. Kwan JA, Schulze CJ, Wang W, Leon H, Sariahmetoglu M, Sung M, Sawicka J, Sims DE, Sawicki G, Schulz R. 2004. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J 18:690-692.
28. Lewis MP, Tippett HL, Sinanan AC, Morgan MJ, Hunt NP. 2000. Gelatinase-B (matrix metalloproteinase-9; MMP-9) secretion is involved in the migratory phase of human and murine muscle cell cultures. J Muscle Res Cell Motil 21:223-233.
29. Llano E, Pendas AM, Freije JP, Nakano A, Knauper V, Murphy G, Lopez-Otin C. 1999. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Res 59:2570-2576.
30. Lovett DH, Mahimkar R, Raffai RL, Cape L, Maklashina E, Cecchini G, Karliner JS. 2012. A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One 7:e34177.
31. Masure S, Paemen L, Van Aelst I, Fiten P, Proost P, Billiau A, Van Damme J, Opdenakker G. 1997. Production and characterization of recombinant active mouse gelatinase B from eukaryotic cells and in vivo effects after intravenous administration. Eur J Biochem 244:21-30.
32. Mathisen B, Lindstad RI, Hansen J, El-Gewely SA, Maelandsmo GM, Hovig E, Fodstad O, Loennechen T, Winberg JO. 2003. S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis 20:701-711.
33. Miyazaki D, Nakamura A, Fukushima K, Yoshida K, Takeda S, Ikeda S. 2011. Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers. Hum Mol Genet 20:1787-1799.
34. Pattwell DM, McArdle A, Morgan JE, Patridge TA, Jackson MJ. 2004. Release of reactive oxygen and nitrogen species from contracting skeletal muscle cells. Free Radic Biol Med 37:1064-1072.
35. Pirila E, Maisi P, Salo T, Koivunen E, Sorsa T. 2001. In vivo localization of gelatinases (MMP-2 and-9) by in situ zymography with a selective gelatinase inhibitor. Biochem Biophys Res Commun 287:766-774.
36. Powers SK, Talbert EE, Adhihetty PJ. 2011. Reactive oxygen and nitrogen species as intracellular signals in skeletal muscle. J Physiol 589:2129-2138.
37. Rodriguez D, Morrison CJ, Overall CM. 2010. Matrix metalloproteinases: What do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta 1803:39-54.
38. Rullman E, Norrbom J, Stromberg A, Wagsater D, Rundqvist H, Haas T, Gustafsson T. 2009. Endurance exercise activates matrix metalloproteinases in human skeletal muscle. J Appl Physiol 106:804-812.
39. Ruta A, Mark B, Edward B, Jawaharlal P, Jianliang Z. 2009. Nuclear localization of active matrix metalloproteinase-2 in cigarette smoke-exposed apoptotic endothelial cells. Exp Lung Res 35:59-75.
40. Schiaffino S, Reggiani C. 2011. Fiber types in mammalian skeletal muscles. Physiol Rev 91:1447-1531.
41. Solli AI, Fadnes B,Winberg JO, Uhlin-Hansen L, Hadler-Olsen E. 2013. Tissue-and cell-specific co-localization of intracellular gelatinolytic activity and matrix metalloproteinase 2. J Histochem Cytochem 61:444-461.
42. Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-Lopez NL, Schulz R. 2007. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol 43:429-436.
43. Vandooren J, Van den Steen PE, Opdenakker G. 2013. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade. Crit Rev Biochem Mol Biol 48:222-272.
44. Viappiani S, Nicolescu AC, Holt A, Sawicki G, Crawford BD, Leon H, van MT, Schulz R. 2009. Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol 77:826-834.
45. Visse R, Nagase H. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 92:827-839.
46. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. 2002. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106:1543-1549.
47. Yang Y, Candelario-Jalil E, Thompson JF, Cuadrado E, Estrada EY, Rosell A, Montaner J, Rosenberg GA. 2010. Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J Neurochem 112:134-149.
48. Yeghiazaryan M, Zybura-Broda K, Cabaj A, Wlodarczyk J, Slawinska U, Rylski M, Wilczynski GM. 2012. Fine-structural distribution of MMP-2 and MMP-9 activities in the rat skeletal muscle upon training: A study by high-resolution in situ zymography. Histochem Cell Biol 138:75-87.
49. Zucker S, Cao J, Chen WT. 2000. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19:6642-6650.